Form 4: Vertex Pharmaceuticals EVP and CMO, Carmen Bozic, Reports Acquisition of Common Stock

Carmen Bozic, EVP and CMO of Vertex Pharmaceuticals, reports the acquisition of common stock related to performance stock unit awards.

Summary

• Carmen Bozic, EVP and CMO of Vertex Pharmaceuticals, filed a Form 4 on February 6, 2025, reporting changes in beneficial ownership.
• The report details the acquisition of 10,262 shares of common stock related to a performance stock unit award granted on February 1, 2022.
• Additionally, 5,928 shares were acquired related to a performance stock unit award granted on February 7, 2024.
• The performance goals for both awards were certified by the issuer's management development and compensation committee on February 4, 2025.
• Following these transactions, Bozic directly owns 39,449 shares of Vertex Pharmaceuticals common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects the achievement of performance goals, leading to stock vesting. It's a routine filing, but the achievement of goals is a positive indicator.

Positives

• The acquisition of shares indicates that performance goals were met, which could be viewed positively.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in the pharmaceutical industry.

Comparison to Industry Standards

• Executive compensation packages including performance-based stock units are standard practice among publicly traded pharmaceutical companies such as Amgen, Gilead Sciences, and Regeneron.
• The vesting schedules and performance metrics associated with these awards are typically detailed in the company's proxy statements.

Stakeholder Impact

• Shareholders may view the vesting of performance-based stock units as a positive sign, indicating that company goals are being met.
• Employees may be motivated by the potential for similar performance-based compensation.

Key Dates